Brand-name drug · GLP-1 receptor agonist
Ozempic (semaglutide)
From the FDA label, read Published by PepVault
Ozempic is a prescription medicine from Novo Nordisk whose active ingredient is semaglutide, sold both as a once-weekly injection and as a once-daily tablet.
FDA approved it, together with diet and exercise, to improve blood sugar control in adults with type 2 diabetes, and to lower the risk of heart attack, stroke and heart-related death in adults with type 2 diabetes who have heart disease or are at high risk.
- Active ingredient
- Semaglutide, Semaglutide (oral)
- Maker
- Novo Nordisk
- Class
- GLP-1 receptor agonist
- FDA application
- NDA 209637, first approved 2017
What FDA approved it for
The injection carries three approved uses: blood sugar control in adults with type 2 diabetes; lowering the risk of major heart events in adults with type 2 diabetes and established heart disease; and lowering the risk of kidney decline, kidney failure and heart-related death in adults with type 2 diabetes and chronic kidney disease.
Ozempic tablets share one label with Rybelsus. They are approved for blood sugar control in adults with type 2 diabetes and to lower the risk of major heart events in adults with type 2 diabetes at high risk of them; the kidney use belongs to the injection alone.
From the label: 1 Indications and Usage.
How it is supplied
| Form | Doses |
|---|---|
| Multi-dose pen (4 weekly doses) | 0.25 mg or 0.5 mg, 1 mg, 2 mg |
| Single-dose prefilled syringe | 0.25 mg, 0.5 mg, 1 mg |
| Tablet | 1.5 mg, 4 mg, 9 mg |
From the label: 3 Dosage Forms and Strengths.
The label’s dosing schedule
This is the dosing schedule as the FDA label states it. A prescriber sets the actual dose and when it changes; it is not an instruction to the reader.
Ozempic injection, once a week
| Dose | When, on the label |
|---|---|
| 0.25 mg a week | Weeks 1 to 4 |
| 0.5 mg a week | After the first 4 weeks |
| 1 mg a week | After at least 4 weeks on 0.5 mg, if needed |
| 2 mg a week | After at least 4 weeks on 1 mg, if needed |
The first month at 0.25 mg is there to lower the chance of stomach side effects; the label places the lasting dose at 0.5 mg, 1 mg or 2 mg, chosen by how blood sugar responds.
For adults with type 2 diabetes and chronic kidney disease, the label sets the lasting dose at 1 mg a week, reached after at least 4 weeks on 0.5 mg.
Ozempic tablets, once a day
| Dose | When, on the label |
|---|---|
| 1.5 mg a day | Days 1 to 30 |
| 4 mg a day | Days 31 to 60 |
| 9 mg a day | From day 61, if more control is needed |
The 1.5 mg tablet is a starting step only; the label says it does not control blood sugar on its own.
Someone on the 0.5 mg weekly injection can move to the tablets: the label starts 4 mg or 9 mg tablets one week after the last shot.
From the label: 2.2 Recommended Dosage; 2.2 Recommended Starting, Escalation and Maintenance Dosage of RYBELSUS and OZEMPIC Tablets; 2.4 Switching from OZEMPIC Injection to RYBELSUS or OZEMPIC Tablets.
How it’s taken
The injection goes under the skin of the belly, thigh or upper arm once a week, on the same day each week, at any time of day, with or without food. The label asks for a different spot each week when the same area is used.
The weekly day can move, as long as at least 2 days pass between two doses.
An Ozempic tablet is swallowed whole each morning on an empty stomach with up to 4 ounces of plain water, and the label asks for a wait of at least 30 minutes before food, drinks or other pills.
From the label: 2.1 Important Administration Instructions.

If a dose is missed
A missed weekly injection is taken as soon as possible within 5 days. Past 5 days, the label skips it and the next dose comes on the usual day.
A missed tablet is skipped, and the next one is taken the following day.
From the label: 2.1 Important Administration Instructions.
Storage
A new pen stays in the fridge at 36°F to 46°F and must never be frozen. Once in use, a pen keeps for 56 days at room temperature (59°F to 86°F) or in the fridge, with the cap on and no needle attached.
The prefilled syringes live in the fridge too, and can spend up to 28 days at 46°F to 86°F if needed.
Ozempic tablets sit at room temperature, 68°F to 77°F, in the bottle they came in.
From the label: 16 How Supplied/Storage and Handling.
Side effects and warnings
| Reaction | Placebo | 0.5 mg | 1 mg |
|---|---|---|---|
| Nausea | 6.1 | 15.8 | 20.3 |
| Vomiting | 2.3 | 5 | 9.2 |
| Diarrhea | 1.9 | 8.5 | 8.8 |
| Abdominal pain | 4.6 | 7.3 | 5.7 |
| Constipation | 1.5 | 5 | 3.1 |
Most of the nausea, vomiting and diarrhea came while the dose was being raised. Stomach side effects led 3.1% of people on 0.5 mg and 3.8% on 1 mg to stop, against 0.4% on placebo.
The boxed warning
The other warnings
Its other warnings cover pancreatitis, eye changes from diabetic retinopathy, low blood sugar when taken with insulin or sulfonylureas, kidney injury from fluid loss, severe stomach side effects, allergic reactions, gallbladder problems and food in the lungs under anesthesia. An Ozempic pen is never shared between people, even with a new needle.
From the label: 6.1 Clinical Trials Experience; Boxed Warning; 5 Warnings and Precautions.
How Ozempic differs from Wegovy and Rybelsus
Ozempic, Wegovy and Rybelsus hold the same active ingredient, semaglutide. What sets them apart is on their labels: what each is approved for, the forms it comes in and how high its schedule goes.
| Compared | Ozempic | Wegovy | Rybelsus |
|---|---|---|---|
| Approved for | Type 2 diabetes; heart and kidney risk in type 2 diabetes | Weight reduction; heart risk with obesity; MASH (injection) | Type 2 diabetes; heart risk in type 2 diabetes |
| Forms | Multi-dose pen; Single-dose prefilled syringe; Tablet | Single-dose pen; Single-dose syringe; FlexTouch pen; Tablet | Tablet |
| Label’s dose range | injection: 0.25 mg to 2 mg once a week; tablets: 1.5 mg to 9 mg once a day | injection: 0.25 mg to 7.2 mg once a week; tablets: 1.5 mg to 25 mg once a day | 3 mg to 14 mg once a day |
| Top dose | 2 mg a week; 9 mg a day | 7.2 mg a week; 25 mg a day | 14 mg a day |
| Maker | Novo Nordisk | Novo Nordisk | Novo Nordisk |
What else we have on semaglutide
Semaglutide on PepVault
- Semaglutide in the peptide library
- Semaglutide (oral) in the peptide library
- Semaglutide: half-life
- Semaglutide: side effects
- Semaglutide: how long it takes to work
- Semaglutide (oral): half-life
- Semaglutide (oral): side effects
- Is Semaglutide legal? FDA, DEA and WADA status
- Is Semaglutide (oral) legal? FDA, DEA and WADA status
- Semaglutide dose guide
- Semaglutide (oral) dose guide
The trials, in plain English
Brand against brand
Compound against compound
- Semaglutide vs Tirzepatide
- Retatrutide vs Semaglutide
- Orforglipron vs Semaglutide
- Cagrilintide vs Semaglutide
- Liraglutide vs Semaglutide
- Semaglutide vs Dulaglutide
- Semaglutide vs Semaglutide (oral)
- CagriSema vs Semaglutide
- 5-Amino-1MQ vs Semaglutide
- Semaglutide vs BPC-157
- Semaglutide vs Exenatide
- Semaglutide vs Amycretin
- Semaglutide vs Petrelintide
- Semaglutide vs Ecnoglutide
- Semaglutide vs Efinopegdutide
- Orforglipron vs Semaglutide (oral)
Questions about Ozempic
What is the starting dose of Ozempic?
The label starts the injection at 0.25 mg once a week for 4 weeks, then raises it to 0.5 mg. The tablets’ first step is 1.5 mg once a day for 30 days. Your prescriber sets the schedule.
What is the highest dose of Ozempic?
The label’s maximum for the injection is 2 mg once a week. For the tablets, the schedule tops out at 9 mg once a day.
What if I miss an Ozempic injection?
The label says to take it as soon as possible within 5 days. If more than 5 days have passed, skip it and take the next dose on the usual day.
How long does an Ozempic pen last out of the fridge?
After its first use, the label lets a pen be kept for 56 days at room temperature, 59°F to 86°F, or in the fridge.
Is Ozempic approved for weight loss?
No. Its approved uses are blood sugar control in adults with type 2 diabetes and lowering heart and kidney risks in some of those adults. The semaglutide brand approved for weight is Wegovy.
Sources
- OZEMPIC (semaglutide) injection, for subcutaneous use, FDA label on DailyMed (version 20, published Jun 10, 2026; read Nov 18, 2026)
- RYBELSUS (semaglutide) tablets and OZEMPIC (semaglutide) tablets, for oral use, FDA label on DailyMed (version 14, published Aug 19, 2026; read Nov 18, 2026)
- Drugs@FDA, NDA 209637 (Ozempic, the injection; application first approved 2017)
- Drugs@FDA, NDA 213051 (Ozempic, the tablets, added to the application by supplement 30 on Jan 30, 2026; application first approved 2019)
PepVault is not affiliated with Novo Nordisk. Ozempic is a trademark of its owner.